Drug Profile
Teriparatide transdermal - Zosano Pharma
Alternative Names: B104; B106; Teribone™ transdermal; TH 0229; ThPTH; ThPTH (1-34); ZP-PTHLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator ALZA Corporation
- Developer Asahi Kasei; Zosano Pharma
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Postmenopausal osteoporosis
Highest Development Phases
- Suspended Postmenopausal osteoporosis
Most Recent Events
- 29 Mar 2016 Teriparatide transdermal - Zosano Pharma is available for licensing in World as of 29 Mar 2016. www.zosanopharma.com/
- 29 Mar 2016 Suspended - Phase-I for Postmenopausal osteoporosis in Australia (Transdermal)
- 28 Sep 2015 Eli Lilly terminates its licence for teriparatide transdermal Worldwide